Currently, surgery is the first-choice therapy for patients with acromegaly; adjuvant therapies include drugs such as somatostatin analogues, dopamine agonists, and a growth-hormone-receptor antagonist. As discussed here, such drugs may sometimes be preferable as primary therapy but there is a pressing need for randomized, controlled trials to establish this.
